A Plant-Based Chewing Gum That Could Help Reduce Viruses in Saliva
Everyday actions—breathing, chatting, coughing, or sneezing—can release tiny viral particles into the air. During cold and flu season, or whenever respiratory infections are circulating, these routine moments may contribute to the spread of illnesses such as influenza, herpes simplex viruses, and coronaviruses. In shared environments like homes, offices, classrooms, and public transportation, even normal conversation can become a pathway for germs.
Researchers are now investigating a surprisingly simple concept: a plant-derived chewing gum designed to bind viral particles in saliva, potentially lowering the amount of active virus where transmission often begins.
Can Chewing Gum Play a Role in Reducing Transmission Risk?
Scientists at the University of Pennsylvania are exploring whether a specially formulated gum could help reduce viral load in the mouth. The idea is not to replace vaccines, masks, or hygiene measures—but to add a practical, easy-to-use layer of prevention that fits into daily life.
A key development: this research is progressing beyond early lab work, with ongoing steps toward human evaluation.
What Makes This Experimental Chewing Gum Unique?
Most chewing gum is made for flavor, fresh breath, or stress relief. This new approach uses plant-produced proteins that can capture certain viruses.
Instead of directly “killing” viruses, the gum is designed to trap them—so they are less able to infect cells or spread to other people through saliva droplets.
Penn researchers led by Dr. Henry Daniell have developed two primary strategies:
-
ACE2-based gum (for SARS-CoV-2)
- ACE2 is a protein naturally found in the human body and is known as the receptor SARS-CoV-2 uses to enter cells.
- By adding plant-grown ACE2 (produced in edible plants such as lettuce), the gum acts like a decoy, encouraging the virus to bind to the added ACE2 rather than to human tissues.
-
FRIL-based gum (for influenza and herpes viruses)
- Another version uses lablab beans (hyacinth beans), which contain FRIL, a lectin-like protein.
- FRIL can attach to sugar structures found on the surface of multiple enveloped viruses, including:
- Influenza A (such as H1N1 and H3N2)
- HSV-1 and HSV-2 (herpes simplex viruses)
In lab settings, these proteins may clump viruses together or block viral entry into cells, reducing viral activity in saliva.
What the Lab Results Show So Far
Experiments have been conducted in controlled lab conditions using patient samples and viral models. Highlights include:
- SARS-CoV-2: Gum containing plant-produced ACE2 reduced viral levels in saliva or swab samples by more than 95% in preclinical studies.
- Influenza + herpes: The FRIL (bean-based) gum produced over 95% reductions in lab tests against influenza and herpes viruses using relatively small amounts (about 40 mg of gum material).
- Stability and release: The gum is designed to release active proteins steadily while chewing, and the material has shown strong shelf stability at room temperature—reported as lasting years under clinical-grade quality requirements.
Important context: these results are largely based on in vitro (test-tube) experiments and simulated chewing models, not broad real-world public use. The central goal is to lower viral load in the mouth, which may reduce transmission potential rather than fully prevent infection.
Viruses targeted in published studies include:
- SARS-CoV-2 (with some testing involving variants such as delta and omicron)
- Influenza A (H1N1, H3N2)
- Herpes simplex virus (HSV-1, HSV-2)
How effectiveness is measured:
- Reductions in viral load or viral infectivity, often assessed via lab tools such as plaque reduction assays, with reported neutralization exceeding 95% at defined doses.
Why Target the Mouth?
Focusing on the oral cavity is strategic. For some respiratory viruses, oral spread can be highly efficient, since saliva droplets are expelled during:
- talking
- laughing
- coughing
- sneezing
By reducing the amount of active virus in saliva, the approach aims to interrupt the transmission pathway at its source. If proven effective in humans, a chewable tool could be especially useful in crowded or high-contact settings.
How the Gum Is Made (And Why Shelf Life Matters)
This gum relies on plant biotechnology: functional proteins are produced in edible plants, processed, and formulated into a gum that is intended to feel and taste like conventional products.
Notably, it is designed to be practical:
- no refrigeration required
- long shelf life
- produced to meet stringent quality standards in research settings
Researchers describe it as a prophylactic (preventive) concept, intended to complement—not replace—standard public health protections.
What You Can Do Now While This Research Continues
This antiviral gum is not yet available for consumers, but there are low-cost habits that may support oral health and reduce germ spread:
- Drink enough water to support healthy saliva flow.
- Chew sugar-free gum to stimulate saliva (even regular gum can help flush particles, though it does not contain antiviral proteins).
- Maintain strong oral hygiene
- brush twice daily
- floss consistently
- Use extra precautions when symptomatic, such as masking in close indoor spaces.
- Follow seasonal prevention guidance, including flu vaccination and staying updated on recommended immunizations.
What’s Next: Clinical Trials and Real-World Potential
The ACE2-based gum has moved into Phase I/II clinical trials to assess its impact on viral load in human saliva. Meanwhile, the FRIL-based version is attracting attention due to its potential activity against multiple viruses.
If ongoing trials confirm safety and real-world effectiveness, this type of product could be useful in settings where exposure risk is higher, such as:
- schools
- dental clinics
- airports and public transit
- workplaces during flu season
Recent peer-reviewed publications (including coverage in journals such as Molecular Therapy) suggest the research continues to produce consistent lab results across multiple viruses, and further updates are expected as studies progress.
FAQ
Is this antiviral chewing gum available for purchase today?
No. It is still in the research and clinical trial stage. More testing is required before any public release.
Does it work against every virus?
No. Published lab testing has focused on SARS-CoV-2, influenza, and herpes simplex viruses. It may have broader relevance for enveloped viruses, but it has not been shown to work against all virus types.
Is it considered safe?
In research settings, the materials have been produced under clinical-grade standards, and the bean-based version has been evaluated for certain unwanted compounds. However, safety for public use depends on successful clinical trials and regulatory review. Only use approved products and consult qualified health professionals for medical decisions.
Disclaimer
This article is for informational purposes only and summarizes publicly available research. It does not provide medical advice. This experimental chewing gum is not an approved treatment or proven preventive for any disease. For personalized guidance on preventing or managing illness, consult a licensed healthcare provider. Research is ongoing, and findings may change as new evidence emerges.
